SCHEMBL4190469

SCHEMBL4190469

C1=CC2C=Cc3ccccc3SC2C=C1

nearest known ligand 0.32

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3077211 0.80 IDO1 (0.30) ALOX5
SCHEMBL5737091 0.76
SCHEMBL12199688 0.73 ALOX5 (0.43) ALOX5
SCHEMBL10442401 0.68
SCHEMBL21383118 0.68
SCHEMBL24265597 0.68 MEN1 (0.31)
SCHEMBL3074714 0.68 HTR6 (0.30)
SCHEMBL31301082 0.68
SCHEMBL3074983 0.68 IDO1 (0.36)
SCHEMBL3833168 0.68

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090149442-A1 Atypical antipsychotic agents having low affinity for the D2 receptor KAPUR SHITIJ 2009-06-11 US disclosed
US-20050222121-A1 Atypical antipsychotic agents having low affinity for the D2 receptor KAPUR SHITIJ 2005-10-06 US disclosed
US-20020182594-A1 Chemomagnetic retrieval of CMV and CMV infected cells CHEMOCENTRYX (US) 2002-12-05 US disclosed
US-20020127544-A1 Modulators of US 28 CHEMOCENTRYX 2002-09-12 US disclosed
WO-2002062956-A2 CHEMOMAGNETIC RETRIEVAL OF CMV AND CMV INFECTED CELLS CHEMOCENTRYX, INC. (US) 2002-08-15 WO disclosed
WO-2002017900-A2 MODULATORS OF US28 (CHEMOKINES) FOR TREATING CYTOMEGALOVIRUS INFECTIONS CHEMOCENTRYX, INC. (US) 2002-03-07 WO disclosed
EP-1181294-A1 NOVEL DERIVATIVES AND ANALOGUES OF GALANTHAMIN Sanochemia Pharmazeutika Aktiengesellschaft (AT) 2002-02-27 EP disclosed
WO-2001074820-A1 NOVEL DERIVATIVES AND ANALOGUES OF GALANTHAMIN SANOCHEMIA PHARMAZEUTIKA AKTIENGESELLSCHAFT (AT) 2001-10-11 WO disclosed
US-4101667-A ANTIINFLAMMATORY AGENTS NIPPON CHEMIPHAR CO., LTD. (JP) 1978-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149442-A1 Atypical antipsychotic agents having low affinity for the D2 receptor DRD2, OPRD1, GRIN2A ALOX5 2393/4885
US-20050222121-A1 Atypical antipsychotic agents having low affinity for the D2 receptor DRD2, OPRD1, GRIN2A ALOX5 2393/4885
US-20020127544-A1 Modulators of US 28 CCR8, CCL5, CXCL10 ALOX5 2310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.